Early additional immune-modulators for Mycoplasma pneumoniae pneumonia in children: An observation study

Infection and Chemotherapy

Volumn 46, Issue 4, 2014, Pages 239-247

  Youn, You Sook ^a,b   Lee, Sung Churl ^a   Rhim, Jung Woo ^a,b   Shin, Myung Seok ^a,b   Kang, Jin Han ^a   Lee, Kyung Yil ^a,b  

^a The Catholic University of Korea   (South Korea)

^b Daejeon St Mary's Hospital   (South Korea)

Author keywords

Children; Corticosteroid; Immunoglobulin; Intravenous; Mycoplasma; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; PREDNISOLONE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; AGGLUTINATION TEST; ANTIBIOTIC THERAPY; ANTIBODY TITER; ARTICLE; CASE STUDY; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; COLD AGGLUTINATION TEST; CORTICOSTEROID THERAPY; DISEASE COURSE; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFANT; MAJOR CLINICAL STUDY; MALE; MICRO PARTICLE AGGLUTINATION METHOD; MYCOPLASMA PNEUMONIA; OBSERVATIONAL STUDY; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; SEROCONVERSION; THORAX RADIOGRAPHY;

EID: 84928558346     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2014.46.4.239     Document Type: Article

References (30)

1. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509-21.
2. Eun BW, Kim NH, Choi EH, Lee HJ. Mycoplasma pneumoniae in Korean children: the epidemiology of pneumonia over an 18-year period. J Infect 2008;56:326-31.
3. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010;16:78-86.
4. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, Zhang JZ, Liu YM, Zhang YY, Wang H, Wang C. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infections in China. Clin Infect Dis 2010;51:189-94.
5. Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, Kang HM, Lee J, Ahn YM, Kang YH, Lee JH. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011. Emerg Infect Dis 2013;19:1281-4.
6. Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother 2013;68:506-11.
7. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, Lee BC. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263-8.
8. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 2008;57:223-8.
9. Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobayashi Y, Oka M. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 2007;56:1625-9.
10. Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, Kim JC. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr 2010;10:48.
11. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55:1642-9.
12. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, Saito A, Kondo E, Teranishi H, Ogita S, Tanaka T, Kawasaki K, Nakano T, Terada K, Ouchi K. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother 2013;57:2252-8.
13. Atkinson TP, Balish MF, Waits KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008;32:956-73.
14. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y, Sasaki T. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006;50:709-12.
15. Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Okada T, Matsushima T, Komiyama O, Shoji M, Ebihara T, Ubukata K, Sato Y, Akita H, Sunakawa K, Iwata S. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother 2009;15:380-3.
16. You SY, Jwa HJ, Yang EA, Kil HR, Lee JH. Effects of methylprednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children. Allergy Asthma Immunol Res 2014;6:22-6.
17. Kim DH, Lee KY, Kim MS, Youn YS, Hwang JY, Rhim JW, Kang JH, Lee JS. Corticosteroid treatment in siblings affected with severe Mycoplasma pneumoniae pneumonia. Infect Chemother 2009;41:190-5.
18. Takei T, Morozumi M, Ozaki H, Fujita H, Ubukata K, Kobayashi I, Kadota K, Miyamae T, Yokota S, Iwata S, Takahashi T. Clinical features of Mycoplasma pneumoniae infections in the 2010 epidemic season: report of two cases with unusual presentations. Pediatr Neonatol 2013;54:402-5.
19. Mulholland S, Gavranich JB, Chang AB. Antibiotics for community acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Sys Rev 2010;7:CD004875.
20. Eliakim-Raz N, Robenshtok E, Shefet D, Grafter-Gvili A, Vidal L, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012; 9:CD004418.
21. Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 2012;55:42-7.
22. Lee KY, Rhim JW, Kang JH. Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza infections: a need for early immune-modulators for severe cases. Med Hypotheses 2011;76:64-9.
23. Rhim JW, Lee KY, Youn YS, Kang JH, Kim JC. Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort study. BMC Infect Dis 2011;11:225.
24. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008;29:608-15.
25. Lee KY, Lee JS. Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis. Med Hypotheses 2006;67:848-55.
26. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, Gomez AM, Esposito S, Principi N, Hardy RD. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2012;198:1180-8.
27. Hirao S, Wada H, Nakagaki K, Saraya T, Kurai D, Mikura S, Yasutake T, Higaki M, Yokoyama T, Ishii H, Nakata K, Aakashi T, Kamiya S, Goto H. Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone. FEMS Immunol Med Microbiol 2011;62:182-9.
28. Yun HJ, Kim YH, Hyun MC. The effect of immunoglobulin as adjuvant therapy in pediatric patients with antibiotic ineffective pneumonia. Pediatr Allergy Respir Dis 2010;20:17-22.
29. Attilakos A, Palaiologou P, Lagona E, Voutsioti A, Dinopoulos A. Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin. Pediatr Neurol 2008;38:357-9.
30. Weng WC, Peng SS, Wang SB, Chou YT, Lee WT. Mycoplasma pneumonia-associated transverse myelitis and rhabdomyolysis. Pediatr Neurol 2009;40:128-30.